Insight Molecular Diagnostics (IMDX) Balance Sheet: Assets & Liabilities

Insight Molecular Diagnostics (IMDX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Insight Molecular Diagnostics reported total assets of $25.76M and total liabilities of $57.22M. Shareholders' equity was negative at −$31.46M, meaning liabilities exceed assets. Total debt stood at $3.50M against $11.58M in cash and short-term investments, a net cash position of $8.09M.

Insight Molecular Diagnostics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Insight Molecular Diagnostics Inc. (IMDX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Mar 2024	Dec 2023	Mar 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Mar 2019	Dec 2017
Current Assets
Cash and Cash Equivalents	11.58	8.64	9.43	9.43	19.99	19.99	32.95	7.14	22.07	8.03	7.60
Short-Term Investments	0.00	0.00	0.00	-	0.43	0.43	0.90	0.68	0.38	0.43	0.76
Cash & Short-Term Investments	11.58	8.64	9.43	9.43	20.43	20.43	33.85	7.82	22.45	8.46	8.36
Accounts Receivable	1.13	1.61	0.48	0.48	2.01	2.01	1.44	0.20	0.00	0.00	0.00
Inventory	0.45	0.41	0.00	-	0.00	-	0.30	0.00	0.00	0.00	0.00
Other Current Assets	2.15	0.82	0.78	0.64	3.10	0.98	0.90	0.26	0.51	0.28	0.34
Total Current Assets	15.31	11.76	10.70	10.70	25.54	25.54	39.14	9.23	22.96	8.64	8.53
Non-Current Assets
Property, Plant & Equipment (Net)	2.82	6.32	5.44	5.44	10.85	10.85	8.37	6.52	3.73	0.61	0.82
Long-Term Investments	0.61	1.70	0.00	-	0.00	-	0.00	13.42	10.96	0.00	0.00
Goodwill	0.00	0.00	0.00	-	0.00	-	18.68	9.19	0.00	0.00	0.00
Intangible Assets	0.00	14.61	56.60	56.60	61.63	61.63	61.72	15.01	0.00	0.00	0.75
Other Non-Current Assets	7.03	2.39	2.16	2.16	2.07	2.07	31.65	2.06	2.21	0.26	0.12
Total Non-Current Assets	10.45	23.32	64.19	64.19	74.56	74.56	120.42	46.19	16.90	0.88	1.69
Total Assets	25.76	35.08	74.89	74.89	100.09	100.09	159.56	55.42	39.86	9.52	10.22
Current Liabilities
Accounts Payable	2.54	1.64	0.95	0.95	1.25	1.25	1.81	0.43	0.47	0.17	0.18
Short-Term Debt	1.81	1.30	0.67	-	0.82	-	1.31	2.39	1.59	1.57	1.48
Current Portion of Long-Term Debt	-	-	-	-	-	-	1.31	2.39	-	-	-
Accrued Liabilities	2.06	1.53	-	1.57	-	3.95	3.47	5.75	-	-	-
Other Current Liabilities	7.72	3.70	5.58	0.05	10.04	2.01	1.53	5.75	2.39	3.83	2.80
Total Current Liabilities	12.08	7.28	7.19	7.19	12.11	12.11	14.12	9.00	4.44	5.56	4.45
Non-Current Liabilities
Long-Term Debt	1.69	2.37	2.20	2.20	2.73	2.73	3.55	1.51	4.58	0.53	1.36
Other Non-Current Liabilities	43.46	37.71	45.03	39.90	45.66	45.66	76.68	7.12	0.00	0.00	0.00
Total Non-Current Liabilities	45.15	40.08	47.23	47.23	48.39	53.69	80.23	12.94	4.58	0.53	1.36
Total Liabilities	57.22	47.36	54.42	54.42	60.50	65.80	94.35	21.94	9.02	6.10	5.81
Stockholders' Equity
Common Stock	369.21	338.24	310.30	310.30	294.93	294.93	252.95	157.16	124.58	74.74	59.97
Retained Earnings	-400.76	-350.54	-289.88	-289.88	-260.68	-260.68	-187.77	-123.68	-93.75	-71.32	-54.68
Accumulated Other Comprehensive Income	0.09	0.02	0.05	0.05	0.04	0.04	0.04	0.00	0.00	0.00	-0.89
Shares Outstanding	28.68	17.45	-	8.26	-	5.93	4.61	-	-	-	-
Total Stockholders' Equity	-31.46	-12.27	20.47	20.47	39.59	34.29	65.22	33.48	30.84	3.42	4.40
Total Liabilities & Equity	25.76	35.08	74.89	74.89	100.09	100.09	159.56	55.42	39.86	9.52	10.22

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Insight Molecular Diagnostics Balance Sheet

How much debt does Insight Molecular Diagnostics have?

Insight Molecular Diagnostics had total debt of $3.50M as of Dec 31, 2025, against $11.58M in cash and short-term investments. Total debt was $3.66M a year earlier.

What are Insight Molecular Diagnostics's total assets?

Insight Molecular Diagnostics reported total assets of $25.76M as of Dec 31, 2025, down 26.6% from $35.08M a year earlier. Total liabilities were $57.22M.

What is Insight Molecular Diagnostics's shareholders' equity?

Insight Molecular Diagnostics's shareholders' equity was negative at −$31.46M as of Dec 31, 2025, so its liabilities exceeded its assets.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition